🔗 Share this article US and UK Agree to No-Tariff Deal on Drugs. Conceptual image of medicine exports. Britain and America have announced a important bilateral deal that will maintain no tariffs on British medicine exports being sold in the American market. The Terms of the Pact Under the terms of the agreement, the UK has pledged to increase spending on medicines through the public health system. This pledge secures that duties on these vital products will remain at nothing for a period of 36 months. This agreement follows earlier warnings to hike import taxes on patented pharmaceutical products, with potential rates mentioned as high as one hundred percent. "This arrangement between the UK strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to American-British medicine commerce," a statement declared. Commercial Importance Pharmaceuticals are one of the UK's largest exports to the US, which is by far the largest destination for major UK drugmakers. Trade data indicate that in the year to the end of September, the UK shipped drugs worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that span. "This deal safeguards work, boosts investment and facilitates the UK to become a international leader for medical research," a government official commented. Key British Pledges The deal entails several specific changes from the United Kingdom: Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by 25%. Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period. Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded 20%. Broader Context The pact takes place against a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption. These tensions were exacerbated by assertions that US customers were paying significantly more for the equivalent treatments than patients in the other developed nations. Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while major investments have been directed toward projects in the United States. The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a share of its overall budget over the past decade.
Conceptual image of medicine exports. Britain and America have announced a important bilateral deal that will maintain no tariffs on British medicine exports being sold in the American market. The Terms of the Pact Under the terms of the agreement, the UK has pledged to increase spending on medicines through the public health system. This pledge secures that duties on these vital products will remain at nothing for a period of 36 months. This agreement follows earlier warnings to hike import taxes on patented pharmaceutical products, with potential rates mentioned as high as one hundred percent. "This arrangement between the UK strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to American-British medicine commerce," a statement declared. Commercial Importance Pharmaceuticals are one of the UK's largest exports to the US, which is by far the largest destination for major UK drugmakers. Trade data indicate that in the year to the end of September, the UK shipped drugs worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that span. "This deal safeguards work, boosts investment and facilitates the UK to become a international leader for medical research," a government official commented. Key British Pledges The deal entails several specific changes from the United Kingdom: Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by 25%. Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period. Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded 20%. Broader Context The pact takes place against a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption. These tensions were exacerbated by assertions that US customers were paying significantly more for the equivalent treatments than patients in the other developed nations. Over the last 18 months, several large drug company projects in the UK have been delayed or abandoned, while major investments have been directed toward projects in the United States. The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a share of its overall budget over the past decade.